Identifying molecular drivers of pathology provides potential therapeutic targets. Differentiating between drivers and coincidental molecular alterations presents a major challenge. Variation unrelated to pathology further complicates transcriptomic, proteomic and metabolomic studies which measure large numbers of individual molecules. To overcome these challenges towards the goal of determining drivers of Huntington's disease (HD), we generated an allelic series of HD knock-in mice with graded levels of phenotypic severity for comparison with molecular alterations. RNA-sequencing analysis of this series reveals high numbers of transcripts with level alterations that do not correlate with phenotypic severity. These discorrelated molecular changes are unlikely to be drivers of pathology allowing an exclusion-based strategy to provide a short list of driver candidates. Further analysis of the data shows that a majority of transcript level changes in HD knock-in mice involve alteration of the rate of mRNA processing and/or degradation rather than solely being due to alteration of transcription rate. The overall strategy described can be applied to assess the influence of any molecular change on pathology for diseases where different mutations cause graded phenotypic severity.
Introduction
Identification of remediable pathological molecular processes is a cornerstone of rational therapeutic design. A common first step in this strategy is to search for bio-molecules with levels that differ between normal and pathological states. Powerful techniques involving genomics, proteomics, transcriptomics and metabolomics provide means of simultaneously identifying and reporting the concentrations of thousands of molecules.
Such studies reveal pathologic correlates that broadly fall into one of four classes: pathology drivers, beneficial responders, epiphenomenal changes and false-positives arising from chance. Well-correlated molecular changes that are not pathologic drivers may be useful as state or target engagement biomarkers. False positives are likely to be frequent, especially when obtained by screening large numbers of molecules. Accumulation of falsepositive candidates makes determination of therapeutically relevant drivers, responders, and biomarkers difficult. An alternate strategy to the correlative approach is to exclude candidates that fail to correlate with phenotypic severity. Identification of a molecular change as not correlating with phenotypic severity argues against it being a driver or responder.
This approach may be particularly useful for diseases such as Huntington's disease (HD) that exhibit different intensities of a single pathologic etiology (1) . Caused by inheritance of an expanded CAG/polyglutamine repeat in the Huntingtin gene, this midlife onset neurological disease exhibits wide variation in age of onset. Longer repeat lengths are associated with earlier onset of clinical features (2) . Murine genetic models of HD share this relationship between length and phenotypic onset with the exception of some extremely long transgenic CAG repeat mice (3) (4) (5) .
These models have been used to identify molecular alterations that might drive HD-like abnormalities with the goal of uncovering therapeutic targets (6) (7) (8) . Transcript profiling, for example, revealed several alterations that are also present in HD patient tissues postmortem (9) . These results and the presence of polyglutamine repeats in many other proteins involved in transcription support the hypothesis that the HD mutation acts through transcriptional dysregulation (10) . A speculative extension of this idea is that some transcript level changes drive the pathology of HD and therapies aimed at normalizing these levels might prove therapeutic. Despite the promise of such potential drivers, the field is faced with the challenge of having too many such candidates. In fact, approximately one-third of all transcripts analyzed are found to have altered levels in HD (11) . Enhanced screening methods are needed to narrow this large field of candidates.
We describe an allelic series of knock-in HD mice that allows rank ordering by phenotypic severity and comparison with transcript profiles from RNA-sequencing analysis of four critical members of the series. The mRNA studied was from the area of the brain most severely affected in HD, the striatum. Data were analyzed to assess the power of the method. Correlating transcript levels with phenotypic severity provided at least 7-fold enrichment of driver/responder/biomarker candidates than would be expected by the standard method of repeatedly comparing one line to a control. Genes with transcript levels alterations that do not correlate with phenotypic severity were at least 20-fold more numerous than those correlating. The nature of the changes was explored by analysis of transcripts with more than one distinguishable isoform which showed that most transcript level alterations involve more than just changes in transcription rate. This result implicates the HD mutation in alterations of mRNA processing and/or degradation.
Results

The HD knock-in allelic series
We previously reported a mouse model of HD where gene targeting was used to replace the short CAG repeat of the mouse HD gene with 150 CAGs (12) . This mouse exhibited mild late onset motor, behavioral and neuroanatomic abnormalities consistent with HD (12, 13) . A line congenic to C57BL/6 was derived; then germ line instability in repeat number was exploited to selectively breed longer and shorter repeat variants. The resulting lines with 50, 100, 150, 200, 250 and 315 CAGs were maintained (Fig. 1A) . HD knock-in mice with fewer than 100 CAGs show no overt HD-like abnormalities, 150 CAGs mild symptoms (12) while longer repeats show earlier ages of onset of the same abnormalities (14, 15) .
Reduction in HD mRNA levels with increased repeat size
Longer repeat alleles have lower HD mRNA levels (Fig. 1B) and express expanded polyglutamine HD protein at levels readily detectable by western analysis (Fig. 1C) . Reduction in HD mRNA levels with increasing CAG repeat length is a property shared by the longer repeat length versions of an analogous allelic series derived from the R6/2 transgenic line of mice (Fig. 2) . The R6/2 series was created by random insertion of a portion of the human genomic region containing the promoter and exon 1 of HD with an expanded repeat (16) and breeding of germline repeat size changes to create a series of different repeat lengths each with the same albeit unknown genomic location (5) .
The expression decrease in longer length repeats might explain the diminishing phenotypic abnormalities seen in the and results normalized to β-actin mRNA levels of same sample. White, gray and black shading indicates WT, heterozygous and homozygous for expanded allele, respectively. Error bars indicate standard error of the mean and asterisks show R6/2 series with repeats above ∼300 CAGs in length (3) (4) (5) . These data are consistent with the view that longer repeats produce a more toxic gene product on a per molecule basis but reduced transgene expression of super long repeat lengths diminishes phenotypic effects (3) (4) (5) .
HD-like abnormalities in the HDQ315/+ line
Previous studies on the R6/2 allelic series show decrements in HD-like abnormalities for mice with ∼300 CAGs when compared with 150 CAGs (3) (4) (5) 17) . Unlike the R6/2 series, our knock-in series does not share the reduction in phenotype shown in the transgenic R6/2 series at 300 repeats. The toxicity of the HDQ315 allele is significantly greater than HDQ150 and HDQ200 as suggested by inability to breed HDQ315 allele homozygotes (Table 1) . Longitudinal behavioral analyses of the HDQ315/+ line show deficits as early as 30 weeks which worsen in degree through 65 weeks (Fig. 3) . Neuroanatomic analyses show a decrease in D1 and D2 dopamine receptor binding by 35 weeks of age and a significant decrease in brain weight at 70 weeks, not accompanied by striatal neuronal loss (Fig. 4) . Striatal aggregates immunoreactive to N-terminal HD antibodies were also prevalent at 70 weeks (Fig. 4) .
Ordering by phenotypic severity
These behavioral and neurochemical analyses place the age of onset of mice heterozygous for the HDQ315 allele and the wild-type allele (HDQ315/+) somewhere between the later onset HDQ150/150 and the earlier onset HDQ200/200 lines. This rank ordering is illustrated in Figure 5 which compares body weight loss, rotarod performance and general activity levels for the three lines. Comparison with other data supports this ordering. Between 35 and 40 weeks of age, HDQ315/+ mice show D1 dopamine receptor binding reduced by 25-30% compared with wild type (WT), midway between HDQ150/150 mice (11% reduction) and HDQ200/200 mice (50-60% reduction) (13) . The utility of ranking a heterozygote between two homozygotes is that it results in different orders for phenotypic severity (WT < HDQ150/ 150 < HDQ315/+ < HDQ200/200) and mutant gene dosage (WT < HDQ315/+ < HDQ150/150 and HDQ200/200). Differential ordering dissociates molecular changes more influenced by expression levels of mutant Huntingtin from molecular changes related to the overall toxicity of the mutation.
Rationale for molecular comparisons within the series
The comparison of molecular levels typically involves finding differences between two groups (e.g. mutant versus WT control). In the HD field, where several animal models are available, consensus as to the validity of a changed molecular level is formed by the compilation of varied mutant versus WT comparisons. This approach is based on the assumption that molecular drivers of each mutant's abnormalities are the same. This assumption is also important for the approach described here in which molecular levels are compared simultaneously across several lines. There is support for the view that the drivers in the HD knockin allelic series are similar. First, the mutation is the same except for repeat length. Second, use of congenics reduces genetic background effects. Third and most important, the abnormalities seen are strikingly similar but with different ages of onset suggesting longer repeat lengths accelerate the same toxic processes. Phenotypic similarity also holds true when a specific repeat length is made homozygous. Both HDQ150 and HDQ200 allele homozygotes exhibit strikingly similar behavioral and neuroanatomic features which present at an earlier age than their corresponding heterozygous lines (12) (13) (14) 18) . The HDQ315/+ mice share this similarity in type of abnormality . Further supporting comparisons between homozygous and heterozygous lines is evidence that loss of wild-type HD in homozygotes has little effect on striatal transcript profiles. Ninety four percent concordance is seen between transcript-level alterations HDQ150/ 150 (which lack WT HD) and R6/2-Q150 mice (which have wild-type endogenous HD) (9) . These genetic and phenotypic similarities support the approach of simultaneous comparisons across the allelic series.
Screen for expression correlates and discorrelates
RNA-sequencing analysis was used to assess early changes in striatal transcript levels between WT, HDQ150/150, HDQ315/+ and HDQ200/200 lines. We chose 21 weeks of age given results that some early markers of HD show significantly altered transcript levels at this age and since it was an age early in the course of disease. At this age, stereological results (13, 14, Fig. 4) show no decrease in striatal neuronal number, eliminating skewing of transcript levels secondary to neurodegeneration. The depth of sequencing allowed analyses of transcript levels from 15 543 genes based on the inclusion criteria presented in Materials and Methods. Table 2 shows that the number of transcript levels changing in the same direction versus WT for HDQ150/150, HDQ315/+ and HDQ200/200 mice allowing for different levels of Graphical examples of transcript levels across the series are presented in Figure 6 . The relationships of transcript levels across the series are classified as described in Materials and Methods. Panels A-C show a class termed 'step-wise correlates' which represent driver/responder/biomarker candidates. Panels D-F show a new class that is not possible to identify for individual mutant versus WT comparison studies. This class is termed 'discorrelate' because it indicates there can be no correlation between transcript level and phenotypic severity. It arises when two or more of the members of the series show a trend which is then broken by one or both other members of the series. As such, the discorrelate class consists of transcripts with a high probability of being negative when addressing the hypothesis that a transcript level alteration is driving phenotype. A look at the discorrelate class reveals a shortcoming in a single mutant versus WT analysis that the simultaneous assessment of the several lines of the allelic series overcomes. For example, Figure 6E shows that an experiment assessing Tbr1 mRNA levels in the single HDQ150/150 versus WT comparison would show a large increase with the HD mutation while an experiment that compared HDQ315/+ versus WT would show no change. The great number of such discorrelates suggests single mutant versus WT comparisons often lead to false-positive driver candidates. The potential power to rule out false positives using multiple line comparisons with an ordered grading of phenotypic severity as opposed to treating them as three independent mutant versus WT comparisons is shown in Table 2 . These data show that the multiple comparison approach was at least seven times better at ruling out false driver/responder/biomarker candidates. Furthermore, in Table 3 , a complete list of mRNAs where such classifications have statistical support, discorrelates vastly outnumber step-wise correlates. A wider view of phenotypic classes is presented in Table 4 . In this table, every gene's total mRNA differences between WT and HDQ315/+ groups at same age as determined by t-test shown above bar (*P < 0.05, **P < 0.01 and ***P < 0.001). Statistically significant differences within the HDQ315/+ group between 30-week-old and both 50 and 65 weeks old were found for all six tests shown (P < 0.05 by Kruskal-Wallis non-parametric ANOVA with Dunn's multiple comparison test) showing progression of abnormality with age.
level is classified without regard to statistical significance by allowing different levels of variation. These data reveal that step-wise phenotypic correlates, an indicator of a potential driver/responder/biomarker of pathology, are rare, at least 20-fold fewer were found than discorrelates. Partial correlates, a less stringent classification allowing for some equivalent values, are also typically less prevalent than phenotypic discorrelates. For transcripts with altered levels, phenotypic discorrelates are the largest class, representing thousands of genes.
Graphical examples of transcript levels with respect to mutant gene dosage are shown in Figure 6G -L. Gene dosage ordering provides similar distribution among classes as ordering by phenotypic severity (Table 4 ). The high numbers of partial correlates for a gene dosage ordering suggests that some mRNA-level alterations are more influenced by the concentration of mutant HD gene product than by the toxicity of longer repeat lengths.
We also used QRTPCR to examine three molecular markers for HD commonly used in mouse models. The gene products for cannabinoid receptor 1 (Cnr1), the dopamine receptor D2 (Drd-2), and the protein phosphatase 1 regulatory subunit 1B (Darpp32) were shown to be lowered in HD mice prior to the onset of motor and behavioral abnormalities (18) (19) (20) Consistent with prior studies, transcript-level reductions compared with wild type were shown for all mice with repeat lengths >150 CAGs (Fig. 7) . Each marker has a similar mRNA-level profile across the allelic series with WT having high levels of marker mRNA and HDQ200/200 having the least. Each also has a statistically significant spike for HDQ315/+ indicating their mRNA levels discorrelated with phenotypic severity. Thus the degree of these marker mRNA reductions at 20 weeks is not a predictor of age of onset which has implications for therapeutic strategies designed to normalize their expression levels. This analysis shows the advantage of the use of an allelic series in assessing the contribution of specific molecular alterations to pathology.
Expanded repeat HD mutations effect processing and/or degradation rather than transcription alone
Three factors dictate mRNA levels: transcription, processing (e.g. splicing) and degradation rates. The ability of RNA sequencing to differentiate between isoforms from a single promoter provides a means of assessing the hypothesis that most transcript levels are altered by changing transcription rather than processing or degradation. This is achieved by considering all genes with more than one isoform transcribed from a single promoter. At steady state, these factors are related to each other by the following equation:
, where K T is the rate of production of full-length primary transcript in FPKM produced per sec, P i is the proportion of the mRNA that is processed to that particular isoform, K D is the rate of degradation per second and FPKM i is the measured level of the specified particular isoform. For the major isoform (defined as the isoform with the highest FPKM from its promoter in the WT line) the equation becomes K T × P major = K D,major × FPKM major . For all other isoforms from the same promoter, minor isoforms, the equation becomes K T × P minor = K D,minor × FPKM minor . Dividing the two equations leads to the following relation FPKM minor /FPKM major = (K D,major × P minor )/ (K D,minor × P major ) a ratio we term the P/D ratio because it is dependent only on processing and degradation and independent of the Shown is the number of genes out of 15 543 genes analyzed by RNA sequencing. All transcripts from a single gene combined and classified by relative FPKM between WT, 150 (HDQ150/150), 315 (HDQ315/+) and 200 (HDQ200/200). a Expected is calculated as the product of the proportion of total altered genes of the three mutant versus WT comparisons times total number of genes. b Discrimination ratio is calculated as the observed concordants divided by the step-wise phenotypic correlates shown in the next row above. Bold numbers indicate calculated ratios. Statistical differences by χ 2 (P < 0.0001) were found for all observed and expected concordants. . Asterisks show statistical significance compared with HDQ315/+ mice of most similar age by t-test (*P < 0.05, **P < 0.01 and ***P < 0.001).
Approximately equal numbers of male and female mice were used for each point. 'a' indicates our previously published data adapted from (13) . Lines determined by method of least squares. In each panel, upper, middle and lower lines represent HDQ150/150, HDQ315/+ and HDQ200/200 mice, respectively. by Cuffdiff software based on dispersion model of variances (*P < 0.05, **P < 0.01, ***P < 0.001). Table 5 shows the proportion of transcripts changed in level where P/D ratios also change across a range of allowed variances. A majority of isoforms from genes changed in transcript level between lines show alteration in P/D ratio between WT and each mutant studied. Therefore, expanded CAG repeats usually alter transcript levels with involvement of processing and/or degradation rates rather than transcription rate alone.
Discussion
The analysis of trends across an allelic series reveals several molecular features that are difficult or impossible to determine by multiple mutant versus wild-type comparisons. One feature is the lessening of HD mRNA levels with longer repeats. This effect is also seen for very long CAG repeats in the R6/2 transgene (3-5). Our analysis shown in Figure 2 revealed an unexpected feature of the R6 series. The R6/2Q50 brain transgene mRNA level is 3-fold less than for the R6/2Q110 line. There are several potential explanations for this result. One is that the extra 60 CAGs provide greater stability for the R6/2Q110 transgene mRNA. This does not seem to be the case for the full-length mRNAs from the endogenous locus, as shown in Figure 2B , where the brain knock-in HDQ50 mRNA is greater in level than that of the HDQ100. Alternatively, the location of the transgene might interact with repeat length allowing for an increase of transcription rate by the addition of 60 CAGs. One potential molecular explanation for this scenario is that site of transgene insertion (which is the same for both R6/2Q50 and R6/2Q110) might be in a relatively closed chromatin configuration at 50 CAGs compared with 110 CAGs. This feature is not shared by the endogenous locus suggesting a different potential for transcription at the R6/2 location versus endogenous HD. The allelic series also provides a more powerful means of screening potential driver/responder/biomarker candidates than standard mutant versus wild-type analyses. Enhanced screening methods are needed given the thousands of transcript-level alterations associated with HD (21) . There are practical considerations to be taken into account when using an allelic series for such a screen. First, given the present cost of RNA-sequencing, the addition of several additional lines to make up the series may limit the number of biological replicates that can be performed for an initial screen. This shortcoming is partially compensated by each mutant line in the series being a graded replicate. The strategy of using a low-cost screen with few biological replicates to identify candidate transcripts should be followed by confirmation with a large numbers of biological replicates. Figure 7 shows the use of 9-12 biological replicates for each line in the series using QRTPCR to determine striatal levels of Drd-2, Darpp32 and Cnr1 mRNAs. A second consideration is whether heterozygous and homozygous lines should be compared as members of the same series. Heterozygotes have a single gene dose of an expanded repeat allele and a dose of the wild-type allele. Homozygotes on the other hand have two gene doses of the expanded allele and no wild type. These genetic differences might influence transcript profiles in a series that mixes heterozygous and homozygous members. In this initial study, we chose members solely based on their phenotypic severity. The comparison HDQ315/+ heterozygotes (one mutant, one wildtype dose) to wild type (zero mutant, two wild-type gene doses) to the homozygous HDQ150/150 and HDQ200/200 lines (two mutant, zero wild-type gene doses) was used here to show that gene dosage correlates better than phenotypic severity with the levels of some transcripts (Table 4 and Fig. 6G-I ). The presence of the wild-type allele or gene dosage of the mutant allele might also be responsible for the HDQ315/+ line breaking the downward trend for Drd-2, Darpp32 and Cnr1 mRNAs levels shown in Figure 7 . The validity of comparison between heterozygous and homozygous series members is strengthened by a previous study showing 94% concordance between transcript-level alterations in HDQ150/150 mice (which lack WT HD) and R6/2-Q150 mice (which have wild-type endogenous HD) (9) and the qualitative similarity of the HD-like phenotypes seen in heterozygous and homozygous members of this series. A third practical consideration is the determination of which tissue should be used for RNA sequence analysis. In the case of HD, several brain regions are known to be affected by the expanded repeat mutation (1) . In this initial study, we have chosen to determine the effects of the HD repeat mutation on striatal mRNAs, since it is considered to be the most affected brain region in HD. The analyses of other brain regions and integration of results with those of the striatum will be needed to provide a more complete picture of the effects of expanded repeat mutations in these HD mouse models. There are numerous plausible theories as to the nature of differentially expressed genes associated with disease states. A change in any particular transcript's level might be a downstream effect coincident with but not causally related to pathology. Reproducible members of this class might serve as valuable biomarkers of pathology but not as candidates for therapeutic intervention. Alternately, a transcript's level change may be a protective response to the genetic insult of the expanded repeat in HD. Finally, a transcript's level change might be responsible for some or all of the pathology. Such drivers and protective responders might then be altered in level for therapeutic purposes. There are several potential pitfalls in the path towards a complete classification of transcript levels in HD. The allelic series provides a means of eliminating some of the major experimental pitfalls, most importantly the elimination of false positives caused by normal variation in experiments which assess large numbers of transcripts simultaneously. The allelic series also provides a means of differentiating those candidates where degree of transcript-level alteration follows degree of phenotypic severity (step-wise correlates) from those that might be subject to threshold effects ( partial correlates).
Previous transcript profiling of HD mouse models and postmortem tissues from HD patients has provided lists of genes with consistent expression changes in HD. We took one such list (Table 3 of (21)) and found, of the 149 listed mRNAs, 100 genes met the criteria for inclusion in our RNA-sequencing analysis. Table 6 shows an overview of these HD-related gene expression changes. Surprisingly, there are several discorrelates amongst the HD-related transcripts. This discrepancy may be due to methodological differences given previous studies relied on HD versus normal RNAs assessed with chip hybridization methods. Overall, however, selecting these HD-related candidates enriches the correlate class at the expense of discorrelates showing a concordance with this and previous studies.
Despite this concordance, literature searches with our best driver/responder/biomarker candidates fail to show any previously published work on these genes with regard to HD. As such the seven statistically supported phenotypic correlates presented in Table 3 represent new potential biomarkers or therapeutic targets. There is one neurotransmitter receptor, the μ-type opioid receptor (Oprm1), which is pharmacologically tractable (22) . One has antioxidant function, the extracellular superoxide dismutase [Cu-Zn] (Sod3) whose activity might be replaced by chemical free-radical scavengers (23) . One is involved in neuroprotection, the insulin-like growth factor binding protein 2 (Igfpb2) (24) and the other four are involved in hemoglobin production. Hbb-bs and Hbb-b1 code for hemoglobin β chains while Hbb-a1 codes the α chain. Alas2 codes for the first step in the heme biosynthetic pathway. Although classically considered erythroid specific, expression of hemoglobin has been shown to occur in rodent striatal neurons isolated by laser-capture microdissection (25) . Blood contamination in our experiment was ruled out by assessing the levels of other blood mRNAs Rhag, Spta1 and Epb4.2 which were either absent or at least 6-fold below our lowest FPKM threshold for inclusion in this study (FPKM < 0.052). Although these seven candidates might be molecular drivers of HD pathology, they might also be responding to the presence of the HD mutation in either a beneficial or neutral manner.
Despite the advantages of the allelic series, its use to provide positive correlative results, as most studies do, would be subject to the logical problems of traditional inductivist methods of scientific inquiry (26) . The new discorrelate class, however, provides a means of interpretation that does not rely on induction, rather falsification of the hypothesis that the expression level of a gene drives a pathological process. A discorrelate under any one set of conditions despite correlation under many other conditions argues against that change being a sole driver of pathology. More complex hypotheses involving threshold expression levels sufficient to cause pathology and combinations of expression alterations of groups of genes would also be falsifiable. multiple comparisons test (*P < 0.05, **P < 0.01 and ***P < 0.001). Table 5 . Transcript-level changes with processing and/or degradation rate alteration Allowed variation υ By seeking discorrelates, the potential for eliminating false positives becomes additive between different laboratory environments and conditions. The number of different conditions that might be applied to reveal discorelates is already quite large given the many attempted treatment regimens that have little effect on pathological severity. Such treatments may reveal further discorrelates by having disparate effects on gene expression levels.
The identification of pathological discorrelates is a particularly attractive approach to eliminating pathologically neutral alterations leaving a short list of potential drivers of pathology when one considers there are a finite number of processes, metabolites, proteins or in this case transcripts in human and mouse tissues. For example, the number of protein coding mRNAs in the entire mouse genome is estimated to be ∼30 000 (27) . Since these can now be queried en-mass, analysis of the entire transcriptome to reveal a complete short list of therapeutically relevant changes is within reach. The addition of the simultaneous assessment of several members of an allelic series adds the power of enhanced discrimination to this approach. This work represents a first step of its type towards ultimately saturating the transcriptome to determine which, if any, are therapeutically relevant molecular alterations. This approach is applicable to any measurable molecular level or process for any disease where a graded pathology exists or can be experimentally produced.
Materials and Methods
Generation of allelic series
The original HD knock-in line (12) was backcrossed to C57BL/6J mice for 10 generations to establish congenic lines containing the expanded repeat mutation. Germline instability of the CAG repeat number was exploited to choose longer and shorter CAG repeat lengths for breeding of individual lines with different repeat lengths. To confirm that the lines used in this study were congenic to C57BL/6J we analyzed our RNA sequencing results by alignment to the C57BL/6J genome (mm10 from UCSC) using the aligner STAR (version 2.5.0b) in 2-pass mapping mode. Variants were called using GATK (version 3.5) following their Best Practices Guide. Sequences that differed from C57BL/6J were considered candidates for comparisons between each mutant and the wild type line. These candidates were well dispersed throughout the mouse genome representing every chromosome with an average distance between candidates of 1.2 million bases. The HDQ200/ 200 line had 2 of 403 candidates with sequences differing from the WT line. The HDQ150/150 line had 1 of 359 and the HDQ315/ + line had 0 sequence differences of 392 candidates. This analysis shows >99.5% sequence identity between the C57BL/6J wild-type line and each mutant line as well as only three sequence variations between mutants and C57BL/6J wild-type controls in over 25 million reads per line. These results are consistent with all mutant lines being congenic to C57BL/6J. 70-week-old HDQ315/+ mice and an age matched wild-type control. Brains fixed overnight in 4% paraformaldehyde were cryoprotected and stored at −80°C; 30 μm coronal sections were cut using a freezing, sliding microtome. Sections were stained using the HD N-18 primary antibody (8767, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a Cy3 conjugated anti-goat IgG antibody (705-165-003, Jackson ImmunoResearch, West Grove, PA, USA). The stained sections of the striatum were digitized using an Olympus DP73 camera, and images were taken using Olympus fluorescence microscope with 552-565 nm filter (WIG cube) for Cy3-antibody detection. An inverted grayscale image of antibody fluorescence was created using Adobe Photoshop software for Figure 4G and H. Stereology was performed as in Kumar et al. (30) .
Analyses of DNA, mRNA and protein
Genotyping was performed by PCR across the repeats using reactions with final concentrations indicated: 10 ng/μl each primers CCCATTCATTGCCTTGCTG and GCGGCTGAGGGGGTTGA, 2  betaine, 400 μ dNTPs, 15 m Tris-HCl, pH 8.9, 8 m ammonium sulfate, 75 μg/ml BSA, 1.25 m MgCl and 0.5 m β-mercaptoethanol and 2.0 ng/μl tail biopsy DNA and 0.04 U/μl LA Taq (TaKaRa). Reactions were carried by incubating 94°C 5 min, then 30 cycles of 94°C 30 s, 53°C 30 s, 72°C 3 min and following cycling 72°C 5 min. PCR products were analyzed by running on long 1% agarose gels, stained with ethidium bromide and visualized with UV light. All samples were compared with standards sized independently by Laragen, Inc. (Los Angeles, CA, USA) and mice >15 CAGs from target length were excluded. R6 mice were genotyped by Laragen. Allele-specific HD QRTPCR was previously described by us in 15.
RNA preparation was performed as previously described (29) . cDNA for QRTPCR was made using 200 ng of sample RNA by the Applied Biosystems Reverse Transcription kit according to manufacturer instructions (Life Technologies, Grand Island, NY, USA). Assays for markers used pre-made Taqman primers and probes and mastermix from Appliedbiosystems Cnr1 (Mm01212171), Drd-2 (Mm00438545), DARPP32 (Mm00454892) and mouse β-actin control (4352341E). HD QRTPCR was as previously described (29) . R6 transgene mRNA levels were determined by QRTPCR as we previously described (30) on RNA extracted from single hemispheres of brain at 6 weeks of age. All QRTPCR assays were performed in an ABI Prism 7900HT (Life Technologies, Grand Island, NY, USA). Groups included from 9 to 12 mice aged 24 ± 4 weeks. Western analysis was performed as previously described (30) but with 4-8% gradient polyacrylamide gels using primary antibodies against HD (MAB2166, Millipore, Darmstadt, Germany), polyglutamine (MAB1574, Millipore) and α-tubulin (T5168, Sigma, St Louis, MO, USA).
For RNA-sequencing analysis striatal mRNA samples of each genotype were pooled such that each mouse contributed equal amounts of total RNA to one of the four different groups: (i) WT n = 12 age 21.7 ± 0.1 weeks, (ii) HDQ150/150 n = 6 age 20.2 ± 0.1 weeks, (iii) HDQ315/+ n = 8 age 21.1 ± 0.6 weeks and (iv) HDQ200/ 200 n = 10 age 21.1 ± 0.6 weeks. Each group had an equal number of males and females. RNA quality was confirmed using the Agilent 2100 Bioanalyzer according to manufacturer instructions followed by two rounds of mRNA purification using oligo dT magnetic beads and cDNA synthesis using SureSelect Strand-specific RNA Library generation kit (Agilent, Santa Clara, CA, USA). cDNA production included fragmentation, repair of ends, A-tailing and the ligation of separate barcode identifiers for each of the four samples. cDNA libraries were quantitated using qPCR in a Roche Lightcycler 480 with a kit for library quantitation (Kapa Biosystems, Woburn, MA, USA). Paired end 2 × 50 bp sequencing runs were performed in the Illumina HiSeq2500. Sequence data were converted to FASTQ Sanger format using Illumina's bcl2fastq version 1.8.4 and aligned to the University of California, Santa Cruz mouse mm10 genome using TopHat version 2.0.11 and the short read aligner Bowtie version 2.1.0. Cufflinks version 2.1.1. was used to assemble transcripts and estimate abundances. Cuffdiff was used to find significant changes in transcript level for all six possible pairwise comparisons of the four samples (shown in Table 3 ).
Further refinement of the data was carried out in Excel spreadsheets. A lower cutoff for FPKM values of 0.3334 was established using Cuffdiff readouts by determining the minimum FPKM value that provided a status of OK (rather than NOTEST) when compared with a zero FPKM value for each of the six pairwise comparisons and averaging the six. To insure 5′ ends were represented fully, we defined 103 groups based on length of transcript and plotted the average counts of each group against median length of each group. In theory, longer transcripts should have more counts, however, we found a plateau starting after 4186 bp. Visual inspection of number of reads on longer transcripts confirm a large drop off in reads more than ∼4 kb from the polyA tail. Since half of the mice used were female, we also excluded Y-chromosome-encoded genes. Furthermore, since small changes in mitochondrial number between lines might have a dramatic effect on transcript levels of mitochondrial encoded genes, we limited our analyses to nuclear-encoded genes. Thus we only include transcripts based on the following inclusion criteria: (i) maximum transcript length for a gene is <4186 bp, (ii) at least one FPKM value for any comparison is >0.3334, (iii) gene is nuclear encoded and (iv) gene is not on the Y-chromosome.
Definitions of classes
For data in Tables 2, 4 The 'step-wise correlate' class exhibits mRNA levels that either decrease or increase with phenotypic severity having FPKM values described as WT ± υ > 150 ± υ > 315 ± υ > 200 ± υ OR WT ± υ < 150 ± υ < 315 ± υ < 200 ± υ:
The 'partial correlate' class is a less stringent form of the 'step-wise' class allowing for some equivalent values having FPKM values that are not all equal, are not 'step wise' and conform to the following WT ± υ 150 ± υ 315 ±υ 200 ± υ OR WT ± υ 150 ± υ 315 ± υ 200 ± υ:
The 'discorrelate' class exhibits a clear breakage of correlation between mRNA level and phenotypic severity with FPKM values described as any of the following WT ± υ < 150 ± υ and 150 ± υ > 315 ± υ or 200 ± υ OR WT ± υ > 150 ± υ and 150 ± υ < 315 ± υ or 200 ± υ OR WT ± υ or 150 ± υ < 315 ± υ and 315 ± υ > 200 ± υ OR WT ± υ or 150 ± υ > 315 ± υ and 315 ± υ < 200 ± υ:
For ordering based on mutant gene dosage, WT has 0 mutant gene doses, HDQ315/+ has one and both HDQ150/150 and HDQ200/200 have 2. Thus leading to the ordering (WT < HDQ315/+ < HDQ150/150 and HDQ200/200) and definitions below. The 'No effect' class exhibits no change in levels across the series having FPKM values described as
The 'step-wise correlate' class exhibits mRNA levels that either decrease or increase with mutant gene dosage while 150 and 200 are equivalent allowing for reasonable experimental error having FPKM values described as WT ± υ > 315 ± υ > 200 ± υ and 150 ± υ and 200 ± 6% ¼ 150 ± 6% OR WT ± υ < 315 ± υ < 200 ± υ and 150 ± υ and 200 ± 6% ¼ 150 ± 6%:
The 'partial correlate' class is a less stringent form of the 'step-wise' class allowing for some equivalent values having FPKM values that are not all equal, are not 'step-wise' and conform to the following:
WT ± υ 315 ± υ 200 ± υ and 150 ± υ OR WT ± υ 315 ± υ 200 ± υ and 150 ± υ:
The 'discorrelate' class exhibits a clear breakage of correlation between mRNA level and gene dosage with FPKM values described as any of the following WT ± υ < 315 ± υ and 315 ± υ > 200 ± υ or 150 ± υ OR WT ± υ > 315 ± υ and 315 ± υ < 200 ± υ or 150 ± υ OR WT ± υ < 315 ± υ and WT ± υ > 200 ± υ or 150 ± υ OR WT ± υ > 315 ± υ and WT ± υ < 200 ± υ or 150 ± υ OR WT ± υ < 150 ± υ and 200 ± υ < WT ± υ or 315 ± υ OR WT ± υ > 150 ± υ and 200 ± υ > WT ± υ or 315 ± υ OR 315 ± υ < 150 ± υ and 200 ± υ < WT ± υ or 315 ± υ OR 315 ± υ > 150 ± υ and 200 ± υ > WT ± υ or 315 ± υ:
Data and mouse line sharing
RNAseq data are available from NCBI's Gene Expression Omnibus accession number GSE73743. Mouse lines are available from the Jackson Laboratory, Bar Harbor, ME, USA (stock numbers 016521-016525 and 004595).
